PubMed Health⌕ Search

PubMed · 7892526

[Nitric oxide].

Abstract

Nitric oxide was identified as the relaxing factor derived from the endothelium in 1987. Nitric oxide synthesis allows the vascular system to maintain a state of vasodilation, thereby regulating arterial pressure. Nitric oxide is also found in platelets, where it inhibits adhesion and aggregation; in the immune system, where it is responsible for the cytotoxic action of macrophages; and in the nervous system, where it acts as neurotransmitter. A deficit in endogenous synthesis of nitric oxide contributes to such conditions as essential arterial hypertension, pulmonary hypertension and heart disease. An excess of nitrous oxide induced by endotoxins and cytokinins, meanwhile, is believed to be responsible for hypotension in septic shock and for hyperdynamic circulatory state in cirrhosis of the liver. Nitric oxide has also been implicated in the rejection of transplanted organs and in cell damage after reperfusion. Inhaled nitrous oxide gas reduces pulmonary hypertension without triggering systemic hypotension in both experimental and clinical conditions. It also produces selective vasodilation when used to ventilate specific pulmonary areas, thereby improving the ventilation/perfusion ratio and, hence, oxygenation. Nitric oxide inhalation is effective in pulmonary hypertension-coincident with chronic obstructive lung disease, in persistent neonatal pulmonary hypertension and in pulmonary hypertension with congenital or acquired heart disease. Likewise, it reduces intrapulmonary shunt in acute respiratory failure and improves gas exchange. Under experimental conditions nitric oxide acts as a bronchodilator, although it seems to be less effective for this purpose in clinical use.(ABSTRACT TRUNCATED AT 250 WORDS)

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

I Rovira. 1995. [Nitric oxide].. https://pubmed.ncbi.nlm.nih.gov/7892526/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Sex differences in bronchiolar epithelium response after the inhalation of lead acetate (Pb).

In order to identify if there were sex differences in lead (Pb) lung concentrations and in bronchiolar response after its inhalation, a mice inhalation model was conducted. Sixty CD-1 adult mice from each sex inhaled separately, lead acetate 0.1 M for 1 h, thrice weekly during 15 days. Animals were evaluated for Pb-lung concentrations by atomic absorption spectrometry and for morphological evaluation by scanning electron microscopy (SEM). Higher Pb-lung concentrations were determined in females, however, more cell damage was found in males, finding that correlated with an increased loss of the nonciliated bronchiolar cells (NCBC) more sloughing and necrosis. Differences in particle clearance, oxidative stress handling, cytokines pathway activation and cytochrome P450 enzymes activity, all influenced by sex hormones, might be a possible explanation for our findings. The relevance of further studies in this field is stressed, as well as its relation to the different development expected for each sex in disease evolution, possible complications and treatment response.

Administration, Inhalation↗

Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect.

This study compares the pulmonary response to an inhaled highly soluble hydrochloride (CAD-HCl) with a low soluble sulphate salt (CAD-SO4) of a dicationic amphiphilic drug (CAD). These salts are known to accumulate in the lung. The bioavailability through gastrointestinal uptake is poor. Wistar rats and beagle dogs received repeated 1 h/day inhalation exposures over 1-4 weeks. The focus of this analysis is to appraise the correlation of markers of effects related to pulmonary phospholipidosis and cytotoxicity relative to the concentration of CAD in the lung tissue, alveolar macrophages and serum. Rats and dogs are known to experience remarkable differences in their respiratory minute volumes and respiratory patterns. In order to facilitate dosimetric comparisons, identical exposure paradigms and methodological procedures were selected. Over a wide range of cumulative dosages, the CADs bound to lung tissue and cells in bronchoalveolar lavage (BAL) paralleled, whilst no clear association existed in terms of plasma concentrations. This suggests that analysis of the fractional loading of BAL-cells (mainly alveolar macrophages) with CAD or CAD-surfactant complexes is amenable to monitor the accumulation of CADs in the lung. In terms of the comparative phospholipidosis-inducing potency, the CAD-HCl was more potent as compared to CAD-SO4. Following dosimetric adjustments, rats and dogs appeared to be equally susceptible to phospholipidosis. In summary, when exposed to equivalent concentrations of CADs, dogs did not demonstrate a markedly different susceptibility than rats. With regard to the relative intensity of changes, the increase of phospholipids in BAL-fluid and especially BAL-cells correlated with the cumulative exposure dose. Thus, with regard to probing the extent of CAD-induced 'overloading' of alveolar macrophages pharmacokinetic determinations in BAL-cells are considered superior to determinations in plasma. Additional advantages of using the alveolar macrophage as denominator to normalize pulmonary drug concentrations include comparisons across species, and exposure regimens are feasible based on almost readily available endpoints in both pre-clinical and selected clinical studies.

Administration, Inhalation↗

Crystalline and amorphous silica differentially regulate the cyclooxygenase-prostaglandin pathway in pulmonary fibroblasts: implications for pulmonary fibrosis.

Inhalation of crystalline (CS) and amorphous silica (AS) results in human pulmonary inflammation. However, silicosis develops only following CS exposure, and the pathogenic mechanisms are poorly understood. This report describes the differential abilities of CS and AS to directly upregulate the early inflammatory mediator COX-2, the recently identified prostaglandin E (PGE) synthase and the downstream mediator PGE2 in primary human lung fibroblasts. Increased cyclooxygenase (COX)-2 gene transcription and protein production were demonstrated by ribonuclease protection assay, Western blot analysis, and immunocytochemistry. In each case the ability of AS to induce COX-2 exceeded that of CS. Similarly, downstream of COX-2, production of the antifibrotic prostaglandin PGE2 was induced in a dose-dependent fashion, but AS was significantly more potent (maximal production: CS = 4,710 pg/ml and AS = 7,651 pg/ml). These increases in COX-2 and PGE2 were preceded by induction of the PGE2 synthase protein, demonstrating the potential role of this novel molecule in silica-mediated inflammation. There was specificity of induction of prostaglandins, as PGF2alpha, but not PGD2, was induced. Using specific COX-2 inhibitors, we showed increased PG production to be dependent on the COX-2 enzyme. Furthermore, stimulation of fibroblasts was particle specific, as silica but not carbon black resulted in fibroblast activation. These results demonstrate that silica can directly stimulate human lung fibroblasts to produce key inflammatory enzymes and prostaglandins. Moreover, they suggest a mechanism to explain the differing fibrogenic potential of CS and AS. The molecules COX-2, PGE synthase, and PGE2 are identified as effectors in silicosis.

Administration, Inhalation↗